Another study showed that a specific SLC26A2-STAS mutation associated with the skeletal disease, diastrophic dysplasia, impairs SLC26A2 trafficking to the plasma membrane (Rapp et al., 2017). This evidence concerns the gene SLC26A2 and bone disorder.